الفهرس 
Introduction & Review of LiteratureOnly 14 pages are availabe for public view
 |  | from | 161 |  |  |
| | | from | 161 | | |
Abstract
Recurrent aphthous ulceration is a chronic inflammatory
disorder characterized by recurrent ulcers affecting the oral
mucosa. RAU remains a clinical problem for many patients and
a major challenge for clinicians. Efforts in prevention and/or
treatment have to date resulted in minimal success at the best.
The present study was carried out on forty minor and
major RAU patients in order to assess the effectiveness of 5%
amlexonox adhesive tablets and low level diode laser in minor
and major RAU management.
In order to study the effectiveness of amlexonox and
LLDL in the management of RAU, ten minor RAU patients and
ten major RAU patients were given 5% amlexonox adhesive
tablets.
The drug was applied three times per day for four days.
Also, ten minor RAU and ten major RAU patients were given
LLDL in one session in continous mode for 5 to 10 seconds. All
participating patients were free from any systemic condition.
History taking and clinical examination including noting
the size, duration, pain severity and recurrence rate of the RAU
lesions was carried out at the time of initial visit, after two days, then after another two days in all groups in order to assess the
effect of 5% amlexonox adhesive tablets and low level diode
laser on these parameters. All patients were followed up weekly
after the trial period for six months to assess recurrence rate.
The results of the present study showed that amlexonox
achieves highest significant induction in the ulcer size in cases
of major RAU and in cases of minor RAU but not high as with
major RAU patients. Amlexonox and LLDL can lead to
complete disappearance of red halo at the end of the trial period
whatever in cases of minor or major RAU.
The current results regarding amlexonox demonstrated
that it achieves highest significant reduction in the pain score in
cases of minor and major RAU. In addition, amlexonox
achieves highest significant reduction in the recurrence rate in
cases of minor and major RAU.
In the present study, LLDL exposure resulted in
significant reduction in the ulcer size in minor RAU patients.
The our results regarding the ulcer size in minor RAU patients
whatever treated with amlexonox or LLDL showed complete
healing at the end of the trial period. In the present study, LLDL and amlexonox showed the
highest significant reduction in the pain score at the end of the
trial period in minor RAU patients [complete pain relief).
LLDL achieves low significant reduction in the
recurrence rate in minor and major RAU patients.